Abstract 143P
Background
The combination of local thermal ablation with immune checkpoint inhibitors perioperatively for small hepatocellular carcinoma (HCC) is yet to be explored. The aim of this phase II trial was to evaluate the safety and tolerability of thermal ablation in combination with tislelizumab, an anti-PD-1 antibody, in patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and to make a preliminary evaluation of the efficacy of this treatment modality.
Methods
This phase II trial (NCT04652440) enrolled newly diagnosed and recurrent HCC patients with 1 or 2 lesions of 2-5 cm in size. This study included two stages. The first stage included 6 patients for dose-limited toxicity (DLT) observation. Only if DLT appeared in < 2 patients, the other 24 patients would be included. Enrolled patients received the first dose of tislelizumab intravenously within 1 day before percutaneous thermal ablation, followed by infusions every 3 weeks for totally 4 doses. The primary endpoints were safety and tolerability. Secondary endpoints included the rate of complete response by first ablation (CR1), local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates.
Results
No DLT occurred in the first 6 patients, and the study completed recruiting a total 30 subjects in July 2023. Twenty-six subjects had already finished their study treatment and were followed regularly. One patient withdrew her informed consent after completion of the ablation and the first dose of study medication. The other 3 were still on tislelizumab therapy. Until the time of data cut-off (July 30, 2023), the most common adverse events were increased alanine aminotransferase (N=15) and aspartate aminotransferase (N=19) on the first day after ablation. The majority recovered after supportive treatment. 10 patients experienced grade 1-2 immune-related adverse events (irAEs), the most common were rash (N=8), pruritus (N=5), and anorexia (N=4). No ≥3 grade irAEs occurred.
Conclusions
Thermal ablation combined with tislelizumab showed acceptable safety and tolerability with no unexpected SAEs observed. Results of efficacy will be disclosed in future.
Clinical trial identification
NCT04652440.
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract